Knight Therapeutics Secures Significant Credit Facility
Knight Therapeutics Inc. (TSX: GUD), a leading pan-American specialty pharmaceutical company, has made a significant stride in its financial capabilities by successfully closing a $100 million secured revolving credit facility. This facility marks a substantial increase from the previously established $50 million revolving credit facility announced earlier in the year.
Expansion and Strengthening of Financial Backing
As part of its strategic growth plan, Knight had previously announced the closure of its $50 million revolving credit facility with National Bank of Canada. This was the first step in a larger endeavor, as the company initiated a syndication process to expand this financial backing to better support its operational strategy.
New Consortium of Lenders
In this new syndication process, Knight has successfully partnered with three additional major banks, including Citibank N.A., Canadian Imperial Bank of Commerce (CIBC), and The Toronto-Dominion Bank. This newly formed banking consortium enhances Knight’s financial network and ensures robust support for its ongoing business initiatives.
Details of the Credit Facility
The newly established credit facility offers Knight substantial financial flexibility, allowing them to access funds as necessary to support its growth trajectory. With an initial maturity set for June 2028, Knight also has the option to extend the facility on an annual basis, further enhancing its financial strategy. Additionally, the facility includes an accordion feature that allows for an additional $100 million, pending acceptance from the lenders.
Usage of Funds
This credit facility is primarily to support Knight's growth strategy, including initiatives like acquisitions and general working capital needs. In fact, Knight recently withdrew C$60 million from the initial facility to fund a portion of the Paladin acquisition. This demonstrates the company's proactive approach in leveraging available financial resources to fuel expansion.
Leadership Commentary on the New Partnership
Arvind Utchanah, Chief Financial Officer of Knight Therapeutics Inc., expressed enthusiasm regarding the new partnership with NBC and the other banks involved in the syndicate. He emphasized that this credit facility effectively doubles their borrowing capacity and significantly enhances their financial flexibility, which is crucial for future growth and acquisition opportunities.
About Knight Therapeutics Inc.
Headquartered in Montreal, Knight Therapeutics is dedicated to acquiring, in-licensing, and commercializing pharmaceutical products primarily for Canada and Latin America. The company operates through its subsidiaries that function under different brands, showcasing a strong commitment to delivering healthcare solutions to diverse regions.
Contact Information
For further inquiries, the contact details for Knight Therapeutics Inc. are as follows:
Investor Contact:
Samira Sakhia, President & Chief Executive Officer
Arvind Utchanah, Chief Financial Officer
T: 514.484.4483
Email: IR@knighttx.com
Website: www.knighttx.com
Frequently Asked Questions
What is the purpose of the $100 million credit facility?
The credit facility is primarily intended to support Knight's growth strategy, along with serving for working capital and other corporate needs.
Who are the lenders involved in this new credit facility?
The lenders include National Bank of Canada, Citibank N.A., CIBC, and The Toronto-Dominion Bank.
How does this credit facility improve Knight's financial flexibility?
This facility doubles Knight's borrowing capacity from $50 million to $100 million, providing more options for funding future acquisitions and growth initiatives.
What are the maturity terms of this credit facility?
The initial maturity date is set for June 17, 2028, with options for annual extensions available.
What recent acquisition did Knight Therapeutics pursue with these funds?
Recently, Knight withdrew C$60 million from the credit facility to partially fund the acquisition of Paladin, illustrating the strategic use of these financial resources.
